专利检索 ap:("THE GEORGE WASHINGTON UNIVERSITY") AND inv:"William B. WEGLICKI" 第 1 页

1.

发明申请
USE OF NK-1 RECEPTOR ANTAGONISTS FOR TREATING HYPOMAGNESEMIA, NEUROGENIC INFLAMMATION, AND CARDIAC DYSFUNCTION ASSOCIATED WITH EGFR-BLOCKING DRUGS 有权
标题翻译：使用NK-1受体拮抗剂治疗与EGFR阻断药相关的高血压，神经源性炎症和心脏功能障碍

公开(公告)号：US20170014420A1

公开(公告)日：2017-01-19

申请号：US15278192

申请日：2016-09-28

申请人： THE GEORGE WASHINGTON UNIVERSITY

发明人： William B. WEGLICKI , Iu Tong MAK

IPC分类号： A61K31/5377

CPC分类号： A61K31/5377 , A61K31/00 , A61K31/4035 , A61K31/444 , A61K31/495 , A61K31/4985 , A61K31/5355

摘要： The present disclosure provides methods for alleviating or preventing the negative physiological side effects associated with the administration of EGFR blocking therapeutics. The disclosure provides, inter alia, methods for treating or preventing: hypomagnesemia, cardiac dysfunction, and skin lesions, which are induced by EGFR blocking drugs, by administering an NK-1 receptor antagonist.

摘要翻译： 本公开提供了减轻或预防与EGFR阻断治疗剂的施用相关的负面生理副作用的方法。本公开尤其提供了通过施用NK-1受体拮抗剂治疗或预防由EGFR阻断药物诱导的低镁血症，心脏功能障碍和皮肤损伤的方法。